Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINGOLIMOD HYDROCHLORIDE vs NITHIODOTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Reduction of risk of hospitalization and all-cause mortality in COVID-19 (EUA, no longer authorized)
FDA-approved for the treatment of acute cyanide poisoning,Off-label: May be used for cyanide poisoning due to smoke inhalation or certain chemical exposures
0.5 mg orally once daily
NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Terminal elimination half-life: 2.5–3 hours in adults with normal renal function; prolonged in renal impairment.
Primarily metabolized by cytochrome P450 4F2 (CYP4F2) via omega-hydroxylation; also undergoes hydrolysis by non-CYP enzymes. Minor contribution from CYP3A4.
Sodium nitrite is partially metabolized to nitric oxide and other metabolites; sodium thiosulfate is primarily excreted unchanged in urine, with minor metabolism by rhodanese in the liver and kidneys.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Primarily renal as unchanged drug and metabolites; biliary/fecal excretion minimal (<5%).
>99.7% bound to plasma proteins, primarily albumin and lipoproteins.
Approximately 90% bound to albumin.
Approximately 1700 L (17 ± 6 L/kg) indicating extensive distribution into tissues, including erythrocytes, brain, and adipose tissue.
0.35 L/kg, indicating moderate tissue distribution.
Oral bioavailability is approximately 93% (range 80–100%).
Oral: 60–80% (first-pass metabolism); IV: 100%.
No dose adjustment required for GFR ≥15 m L/min. Fingolimod has not been studied in ESRD (GFR <15 m L/min) or dialysis; use caution.
No dose adjustment required for mild-moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), consider reducing sodium thiosulfate dose by 50% and monitoring serum thiocyanate levels.
Child-Pugh A or B: No dose adjustment. Child-Pugh C: Contraindicated.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-severe (Child-Pugh B/C), use with caution; consider reducing sodium nitrite dose by 50% due to increased methemoglobinemia risk.
For patients ≥10 years and >40 kg: 0.5 mg orally once daily. For patients <40 kg or <10 years: Safety and efficacy not established.
Children: Sodium nitrite 0.15-0.33 m L/kg of 3% solution (4.5-10 mg/kg) IV push over 2 minutes, followed by sodium thiosulfate 1.65 m L/kg of 25% solution (412.5 mg/kg) IV push over 10 minutes. Repeat half doses if symptoms persist.
No specific dose adjustment; use caution due to increased risk of bradycardia, infections, and comorbidities.
Geriatric patients: Use weight-based dosing (same as adult). Start with lower doses (e.g., sodium nitrite 5 mg/kg) due to increased risk of hypotension and methemoglobinemia. Monitor vital signs frequently.
Increased risk of serious infections, including life-threatening opportunistic infections such as progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, and herpes virus infections. Baseline and periodic monitoring required.
None
Risk of bradyarrhythmia and atrioventricular block at treatment initiation; require ECG monitoring. Macular edema, especially in patients with uveitis or diabetes. Reduced pulmonary function; avoid in severe respiratory disease. Posterior reversible encephalopathy syndrome (PRES). Hepatic injury; monitor liver enzymes. Fetal harm; effective contraception required. Increased risk of infections; withhold during serious infection. Avoid live vaccines during and for 2 months after treatment.
May cause severe hypotension, especially in children,Risk of methemoglobinemia with excessive sodium nitrite,Use caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as hemolysis may occur,Monitor methemoglobin levels, blood pressure, and oxygen saturation during therapy,Sodium thiosulfate may cause hypocalcemia in high doses
Hypersensitivity to fingolimod or any component. Recent (within 6 months) myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or NYHA class III/IV heart failure. History of Mobitz type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome unless pacemaker in place. Severe untreated sleep apnea. Baseline prolonged QTc interval (>500 msec) or concurrent Class Ia or Class III antiarrhythmic drugs.
Hypersensitivity to any component of the product,Children under 6 months of age (relative contraindication due to increased risk of hypotension and methemoglobinemia)
Grapefruit and grapefruit juice increase fingolimod exposure by inhibiting CYP3A4 and CYP4F2; avoid concurrent consumption.
No known food interactions. Avoid alcohol as it may impair liver function and worsen acidosis.
First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and increased resorptions. In humans, S1P receptor modulators are associated with a 2-fold increase in major congenital malformations when exposed in the first trimester. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and growth restriction due to maternal lymphopenia and immune modulation.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemoglobinemia and hemolytic anemia due to methylene blue component; avoid near term due to risk of neonatal methemoglobinemia.
Unknown if excreted in human breast milk. M/P ratio not established. Due to potential for serious adverse reactions in breastfed infants (e.g., immunosuppression), advise against breastfeeding during therapy and for 2 months after last dose.
No human data; methylene blue is excreted in breast milk with an M/P ratio of approximately 0.7. Potential for infant methemoglobinemia; caution advised. Consider withholding breastfeeding for 4-6 hours after maternal dose.
No specific dose adjustments established for pregnancy; however, pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Fingolimod is contraindicated in pregnancy due to fetal risk; use only if benefit justifies risk. Discontinue at least 2 months before planned conception due to long half-life (6-9 days).
Standard dosing (1 mg/kg IV) used in pregnancy; consider lower dose (0.5-1 mg/kg) if severe anemia or G6PD deficiency. No routine dose adjustment, but monitor for maternal hypotension and fetal bradycardia.
First-dose monitoring required for 6 hours post-initial dose due to bradycardia risk; obtain baseline ECG, blood pressure, and heart rate. Avoid use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. Vaccinate against varicella zoster virus (VZV) before initiation if no history of chickenpox or vaccination. Monitor for macular edema, especially in patients with diabetes or uveitis. Lymphopenia is expected; do not discontinue for low lymphocyte counts unless infection occurs.
NITHIODOTE (sodium nitrite and sodium thiosulfate) is indicated for acute cyanide poisoning. Administer intravenously as soon as possible after exposure. Monitor methemoglobin levels; do not exceed 20% methemoglobinemia. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Sodium nitrite induces methemoglobinemia which can impair oxygen delivery; ensure adequate ventilation. Sodium thiosulfate is generally safer and can be given separately.
Take exactly as prescribed; do not stop without consulting your doctor.,You will be observed for at least 6 hours after your first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) immediately.,Report any vision changes, such as blurriness or blind spots.,Avoid live vaccines while taking this medication and for 2 months after stopping.,Fingolimod can harm a fetus; use effective contraception during treatment and for 2 months after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
This medication is only used in hospital settings for cyanide poisoning.,It is given through an IV line as soon as possible after exposure.,You may experience symptoms of low oxygen such as headache, confusion, or blue skin due to methemoglobin formation.,Tell your doctor if you have a history of G6PD deficiency, anemia, or breathing problems.,Follow-up blood tests will be needed to monitor your oxygen levels and blood counts.
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINGOLIMOD HYDROCHLORIDE vs NITHIODOTE, answered by our medical review team.
FINGOLIMOD HYDROCHLORIDE is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.. NITHIODOTE is a Cyanide Antidote that works by Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINGOLIMOD HYDROCHLORIDE and NITHIODOTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINGOLIMOD HYDROCHLORIDE is: 0.5 mg orally once daily. The standard adult dose of NITHIODOTE is: NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINGOLIMOD HYDROCHLORIDE and NITHIODOTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINGOLIMOD HYDROCHLORIDE is classified as Category C. First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and inc. NITHIODOTE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemogl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.